Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

REGNRegeneron PharmaceuticalsSigning up patients

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Relapsed/Refractory Follicular Lymphoma · Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

5Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Nov 4, 2026 · was worth 5, fading over time

    +4.8
Worry score5

Score over time

Stage
Phase 3
Patients
580 (planned)
Started
Dec 28, 2023
Main results expected
Apr 30, 2031
Fully finished
Apr 30, 2031
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide

    Measured over: Up to 35 days

  • Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide

    Measured over: Up to 2 years

  • Severity of TEAEs for odronextamab in combination with lenalidomide

    Measured over: Up to 2 years

  • Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR)

    Measured over: Up to 5 years

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT06149286 · record last updated 2026-10-07 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT06149286) ↗